KEGG   DRUG: Sarilumab
Entry
D10161                      Drug                                   
Name
Sarilumab (USAN);
Sarilumab (genetical receombination) (JAN);
Kevzara (TN)
Product
Formula
C6388H9918N1718O1998S44
Exact mass
144073.5003
Mol weight
144162.2723
Sequence
(Heavy chain)
EVQLVESGGG LVQPGRSLRL SCAASRFTFD DYAMHWVRQA PGKGLEWVSG ISWNSGRIGY
ADSVKGRFTI SRDNAENSLF LQMNGLRAED TALYYCAKGR DSFDIWGQGT MVTVSSASTK
GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVTYL PPSRDELTKN
QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN
VFSCSVMHEA LHNHYTQKSL SLSPGK
(Light chain)
DIQMTQSPSS VSASVGDRVT ITCRASQGIS SWLAWYQQKP GKAPKLLIYG ASSLESGVPS
RFSGSGSGTD FTLTISSLQP EDFASYYCQQ ANSFPYTFGQ GTKLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H143-H199, H219-L214, H225-H'225, H228-H'228, H260-H320, H366-H424, H'22-H'96, H'143-H'199, H'219-L'214, H'260-H'320, H'366-H'424, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Anti-inflammatory
 DG01985  Disease modifying anti-rheumatic drug (DMARD)
Remark
Therapeutic category: 3999
ATC code: L04AC14
Product: D10161<JP/US>
Efficacy
Anti-inflammatory, Antirheumatic, Anti-IL-6 receptor antibody
  Disease
Rheumatoid arthritis [DS:H00630]
  Type
Monoclonal antibody
Target
IL6R (CD126) [HSA:3570] [KO:K05055]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC14 Sarilumab
      D10161  Sarilumab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Interleukin Blockers
    Sarilumab
     D10161  Sarilumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D10161  Sarilumab (USAN); Sarilumab (genetical receombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D10161  Sarilumab
 Anti-inflammatory
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D10161  Sarilumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D10161  Sarilumab
 Antirheumatic agent
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D10161  Sarilumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL6R (CD126)
     D10161  Sarilumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10161
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10161
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10161
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10161
Other DBs
CAS: 1189541-98-7
PubChem: 135626879
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system